Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29392962 | 1.00 | MAPK3 (1.00) | MAPK3MAPK1 | |
| SCHEMBL18256227 | 1.00 | MAPK3 (1.00) | MAPK3MAPK1 | |
| SCHEMBL15938331 | 0.93 | MAPK3 (0.87) | MAPK3MAPK1 | |
| SCHEMBL15938860 | 0.93 | MAPK3 (0.87) | MAPK3MAPK1 | |
| SCHEMBL15937887 | 0.93 | MAPK3 (1.00) | MAPK3MAPK1 | |
| SCHEMBL15938204 | 0.93 | MAPK3 (1.00) | MAPK3MAPK1 | |
| SCHEMBL15942024 | 0.93 | MAPK3 (0.86) | MAPK3MAPK1 | |
| SCHEMBL15938756 | 0.93 | MAPK3 (1.00) | MAPK3MAPK1 | |
| SCHEMBL15938585 | 0.93 | MAPK3 (0.86) | MAPK3MAPK1 | |
| SCHEMBL15951544 | 0.92 | MAPK3 (0.86) | MAPK3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117897159-A | Heterocyclic compounds and methods of use | 安进公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-117881397-A | Heterocyclic compounds and methods of use | 安进公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-117835976-A | Heterocyclic compounds and methods of use | 安进公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-117651700-A | 2-aminobenzothiazole compounds and methods of use | 安进公司 | 2024-03-05 | — | — | CN | disclosed |
| CN-117561063-A | Heterocyclic compounds and methods of use | 安进公司 | 2024-02-13 | — | — | CN | disclosed |
| EP-2953457-B1 | ERK INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2020-04-08 | — | — | EP | disclosed |
| US-20200030355-A1 | COMBINATION THERAPY FOR TREATING CANCER | Epizyme, Inc. | 2020-01-30 | — | — | US | disclosed |
| US-20200030355-A1 | COMBINATION THERAPY FOR TREATING CANCER | Epizyme, Inc. | 2020-01-30 | — | — | US | disclosed |
| EP-3179858-B1 | FORMS AND COMPOSITIONS OF AN ERK INHIBITOR | CELGENE CAR LLC (BM) | 2019-05-15 | — | — | EP | disclosed |
| EP-3179858-B1 | FORMS AND COMPOSITIONS OF AN ERK INHIBITOR | CELGENE CAR LLC (BM) | 2019-05-15 | — | — | EP | disclosed |
| WO-2016025648-A1 | COMBINATIONS OF AN ERK INHIBITOR AND A RAF INHIBITOR AND RELATED METHODS | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| WO-2016025639-A1 | COMBINATIONS OF AN ERK INHIBITOR AND A CHEMOTHERAPEUTIC AGENT AND RELATED METHODS | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| US-20160002176-A1 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160002176-A1 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-01-07 | — | — | US | disclosed |
| EP-2953457-A2 | ERK INHIBITORS AND USES THEREOF | Celgene Avilomics Research, Inc. (US) | 2015-12-16 | — | — | EP | disclosed |
| US-9145387-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-9145387-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| WO-2014124230-A2 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-08-14 | — | — | WO | disclosed |
| US-20140228322-A1 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-20140228322-A1 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002176-A1 | ERK INHIBITORS AND USES THEREOF | MAPK1, MAPK3, MAP4K2 | MAPK3 2/4885MAPK1 1/4885 |
| US-20200030355-A1 | COMBINATION THERAPY FOR TREATING CANCER | DOT1L, CARM1, EHMT1 | MAPK3 2850/4885MAPK1 3366/4885 |
| US-20140228322-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | MAPK3 3/4885MAPK1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.